title: Immunosuppressive treatment of venous allografts.
abstract: In order to evaluate whether temporary immunosuppressive therapy is able to improve the results obtained with viable venous allografts and achieve better results than with synthetic grafts, 142 arterial reconstructions were performed in mongrel dogs bypassing their ligated femoral arteries. Histological as well as immunological studies were performed and patency determined by weekly palpation and regular angiography. The 6-month cumulative patency rates were: Group I: synthetic grafts (a) Dacron: 48%, (b) plasma-TFE: 53%. Group II: fresh grafts (a) autografts: 100%, (b) allografts: 37%, (c) allografts treated with cyclosporin 4 mg kg-1 daily for 1 month: 74% (100% after 1 month). Group III: grafts preserved in Hanks' solution with 15% DMSO at -160 degrees C for 1 month (a) autografts: 77%, (b) allografts: 35%, (c) allografts treated with methylprednisolone 1 mg kg-1 daily: 38%, (e) allografts treated with cyclosporin and methylprednisolone: 83%. Group IV: human saphenous veins implanted as xenografts and treated with cyclosporin and methylprednisolone: 18%. Immunosuppressive therapy with cyclosporin seems to be able to prevent early thromboses due to rejection seen after implantation of viable fresh or cryopreserved venous allografts, and the results are significantly better than those obtained with synthetic grafts. Tissue matching might further improve these results. This study suggests that cryopreserved venous allografts could be used for the creation of a vein-bank and their use, in combination with tissue typing and temporary immunosuppressive therapy may be warranted for arterial reconstructions when autologous saphenous vein is not available.
authors.affiliation: Department of Vascular Surgery, University Hospital Ghent, Belgium.
authors.forename: F
authors.initials: F
authors.lastname: Vermassen
authors.forename: N
authors.initials: N
authors.lastname: Degrieck
authors.forename: L
authors.initials: L
authors.lastname: De Kock
authors.forename: J
authors.initials: J
authors.lastname: Goubeau
authors.forename: K
authors.initials: K
authors.lastname: Van Landuyt
authors.forename: L
authors.initials: L
authors.lastname: Noens
authors.forename: F
authors.initials: F
authors.lastname: Derom
mesh_terms: D000818:Animals; D000961:Antilymphocyte Serum / Q000032:analysis; D001807:Blood Vessel Prosthesis; D016572:Cyclosporine / Q000627:therapeutic use; D004285:Dogs; D005260:Female; D005263:Femoral Artery / Q000601:surgery; D007165:Immunosuppression Therapy; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009926:Organ Preservation; D011093:Polyethylene Terephthalates; D011138:Polytetrafluoroethylene; D014181:Transplantation Immunology; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous; D014654:Vascular Patency; D014680:Veins / Q000637:transplantation*
chemical_list: D000961:Antilymphocyte Serum; D011093:Polyethylene Terephthalates; D016572:Cyclosporine; D011138:Polytetrafluoroethylene; D008775:Methylprednisolone